APONVIE®
Postoperative Nausea and Vomiting (PONV)
ApprovedMarketed
Key Facts
Indication
Postoperative Nausea and Vomiting (PONV)
Phase
Approved
Status
Marketed
Company
About Heron Therapeutics
Heron Therapeutics is a fully integrated biopharmaceutical company with a mission to improve patient lives through best-in-class, non-opioid medicines. The company has successfully commercialized a portfolio of four products targeting postoperative pain (ZYNRELEF®) and nausea/vomiting (SUSTOL®, CINVANTI®, APONVIE®), leveraging its proprietary Biochronomer® drug delivery technology to create sustained-release formulations. Its strategy focuses on addressing significant unmet needs in acute and oncology care by providing long-duration, localized therapy from a single administration, thereby reducing systemic side effects and healthcare burdens associated with opioid use and uncontrolled symptoms.
View full company profileTherapeutic Areas
Other Postoperative Nausea and Vomiting (PONV) Drugs
| Drug | Company | Phase |
|---|---|---|
| BARHEMSYS® (amisulpride) injection | Eagle Pharmaceuticals | Approved/Commercial |
| Astressin Platform | Sentia Medical Sciences | Pre-clinical |